Flagship Pioneering — 2018 Investments
2 investments dated 2018 · listed companies and verified rows first · show all
Sana is a biotech company developing engineered cell medicines, including gene therapies for gene modification and delivery, cell replacement therapies using stem cell biology, and manufacturing solutions to improve patient access to these treatments.
BiotechHealthtechMedical DevicesSeattle, US
Steve Harr(President and Chief Executive Officer)
Board seatGeoffrey von Maltzahn· per SEC Form D
Co-investorsAmerican Family VenturesARCH Venture PartnersF-Prime CapitalInnovating CapitalJDRF T1D FundManta Ray Ventures+1 more
KSQ Therapeutics develops eTIL therapies—engineered tumor-infiltrating lymphocyte treatments for solid tumors—using its proprietary CRISPRomics platform to identify and target novel therapeutic candidates through genome-wide CRISPR/Cas9 functional genomic screens.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Tim Wang(Cofounder)JOHN TRZUPEK, PH.D.(TREASURER, SECRETARY & CHIEF FINANCIAL OFFICER)DAVID P. MEEKER, M.D.(PRESIDENT AND CHIEF EXECUTIVE OFFICER)FRANK STEGMEIER, PH.D.(CHIEF SCIENTIFIC OFFICER)JAMES GILBERT(Director)
BoardALAN L. CRANE(Director)
Co-investorsAlpha Wave GlobalARCH Venture PartnersLAVLilly Asia VenturesBaillie GiffordPolaris Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.